NasdaqGM:PTGXBiotechs
Protagonist Therapeutics (PTGX) Could Be 66% Below Fair Value As Pipeline Progress Lifts Interest
Protagonist Therapeutics (PTGX) drew fresh attention after its stock climbed 7.1% on heavier than usual trading, as investors focused on key pipeline milestones and recent FDA activity related to rusfertide and Icotyde.
See our latest analysis for Protagonist Therapeutics.
At a share price of $140.07, Protagonist Therapeutics has seen strong momentum recently, with a 30 day share price return of 42.88% and a 1 year total shareholder return of 167.87%, which may indicate that investors are...